Form 4: Aquestive Therapeutics Chief Medical Officer Reports Stock Transaction
SEC Form 4 Filing
Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, reports disposition of shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- On August 9, 2024, Carl N. Kraus, the Chief Medical Officer of Aquestive Therapeutics, Inc., reported a transaction involving the company's common stock.
- A total of 10,819 shares were disposed of to satisfy tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs).
- The transaction price was $3.43 per share.
- Following the transaction, Kraus directly owns 251,681 shares of Aquestive Therapeutics.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine transaction related to tax obligations.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations. It doesn't necessarily reflect a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of stock transaction (disposal of shares). |
| 08/12/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.